ORKA•benzinga•
Oruka Therapeutics Initiates Dosing Of Healthy Volunteers In Its First Clinical Trial Of ORKA-002, The Company's Novel, Subcutaneously Administered, Half-life Extended Monoclonal Antibody Targeting IL-17A And IL-17F
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2025 by benzinga